Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne Diab-Endo-Met Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne Diab-Endo-Met conducts studies aimed at improving outcomes for patients with cardiovascular disease.
- Evaluation of new therapies to reduce major adverse cardiovascular events
- Investigation of treatments targeting elevated lipoprotein(a)
- Assessment of drug combinations for hypertension and chronic kidney disease
- Exploration of weight‑loss agents for cardiovascular risk reduction
These trials seek to test innovative medicines, improve risk management, and enhance long‑term heart health.
Nervous System Disease Research
Research at the centre includes studies on nerve complications related to diabetes, such as diabetic peripheral neuropathy.
- Pain relief strategies for diabetic peripheral neuropathy
- Neuroprotective approaches to prevent nerve damage
- Evaluation of novel oral agents for neuropathic pain
- Safety profiling of combination therapies affecting nerve function
The goal is to find effective treatments that alleviate pain and preserve nerve health for patients with diabetes‑related nervous system disorders.
Metabolic and Nutritional Disease Research
The clinic focuses on metabolic disorders such as type 2 diabetes and obesity.
- Testing of glucose‑lowering agents for type 2 diabetes
- Combination therapies involving SGLT2 inhibitors and other oral drugs
- Weight‑management interventions to lower cardiovascular risk
- Studies on kidney function preservation in diabetic patients
These investigations aim to improve blood‑sugar control, support weight loss, and protect kidney health in people with metabolic disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB4active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.7trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne Diab-Endo-Met Sp. z o.o.
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azd5004 | 4 | Unknown | 2025-02-24 | 2025-02-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.